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Abstract
We present the case of a 52 year-old male with a history of C-hepatitis and two liver neoplastic
lesions treated by radiofrequency (RF) ablation. The patient wears an abdominally-implanted
unipolar VVI pacemaker that did not show any signs of interference during RF pulses.
We describe the procedure performed and discuss the present knowledge regarding the possi-
bilities of RF interference with the normal pacemaker functioning in several settings related to
abdominal RF treatments. (Cardiol J 2009; 16, 3: 264–268)
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Introduction
The number of patients with cardiac stimula-
tion devices has been steadily growing over the last
two decades [1]. These patients have also been in-
creasing in age and they can be subject to other di-
seases and diagnostic procedures that can somehow
interact with their stimulation device. On the other
hand, technical advances in all fields of medicine
have allowed patients with serious conditions to
attain a lifespan that could not have been reached
otherwise. They can receive treatments such as
pacemakers for different conditions to improve their
quality of life [2].
Most pacemakers or implantable defibrillators
are at potential risk of electromagnetic interference,
even if they have filters specially designed to avoid
interference with their normal functioning.
Most devices are designed to attenuate any inter-
ference outside the normal limits of 10 to 100 Hz
(the usual range for intracardiac electrograms) [3]
but it is well known that strong electromagnetic
fields such as magnetic resonance imaging or ma-
gnetic catheter navigation systems are associated
with the malfunction of devices or even physical
damage to the circuitry or electrodes [1, 4]. It has
also been described that intracardiac radiofrequen-
cy (RF) ablation procedures can be associated with
pacemaker malfunction requiring different sorts of
interventions [5–7].
Radiofrequency ablation procedures related to
different solid tumors have also increased in recent
years. The technique has become more widely ava-
ilable and has been used in the treatment of hepa-
tic primary tumors or methastasic lesions in that
organ [8, 9]. Nevertheless, experience regarding
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ablation procedures in other intrathoracic or abdo-
minal organs is scarce, and so is the knowledge
about the possible effects of such RF-based proce-
dures on pacemakers’ function. A report by Hayes
et al. [3] showed two cases in two different scena-
rios, one of them referred to as a ‘worst case scena-
rio’. We report here another ‘worst case scenario’
with the aim of adding to the previous knowledge.
Case report
A 52 year-old man was being evaluated for pro-
gressive elevation of a-fetoprotein detected by serial
determinations. He had a history of C virus hepatitis
and chronic hepato-cellular damage. An a-fetoprotein
level of 639 mg/dL prompted a computed tomogra-
phy that was performed a month before the present
intervention. That showed two focal lesions of
approximately 2.5 cm diameter. One of them was
in segment 2 near the hepatic dome; the other one
was lateral, between hepatic segments 4 and 5. Both
lesions showed contrast enhancement and portal
wash-out. The surrounding parenchyma showed
hepato-cellular chronic damage.
The patient had had a rheumatic mitral valve
stenosis diagnosed in 1973 in another hospital. He
was operated on at the time, and a Starr-Edwards
mitral valve prosthesis was installed. He received
several blood transfusions during that surgical pro-
cedure’s perioperative interventions.
The patient was diagnosed with a sinus node
dysfunction in 2002 whose first manifestation was
atrial fibrillation. In September 2004 a VVI pacema-
ker was implanted. This had to be removed and
relocated later that year because of an infection of
the pocket site. After several complications, the
pacemaker had to be relocated to an abdominal po-
sition. The pocket infection prompted an endocar-
ditis episode and so the first mechanical valve had
to be changed and a tricuspid valvuloplasty perfor-
med also. The next year, 2005, follow-up studies
showed a severe para-prosthetic regurgitation. He
then received a new Edwards-Mira mitral prosthe-
sis that has not shown any new complications.
Later in 2005, the pacemaker generator showed
dysfunction data (not specified from the original
hospital) and had to be replaced.
When the patient came to our hospital, he was
wearing a Medtronic Sigma SSI 103® pacemaker,
with the generator in an abdominal position, pro-
grammed in a unipolar stimulation and sensing
mode with an epicardiac ventricular electrode.
On the day of the procedure, the pacemaker
interrogation showed a rate of 60 beats per minute,
pulse width 0.5 ms, amplitude 5 V, sensitivity 2.8,
with a ventricular refractory period of 330 ms, ven-
tricular lead impedance 439 W and unipolar sensing
and pacing mode. Interrogation showed also
2.74 mA battery voltage, 1956 W battery impedance,
measured stimulus amplitude 4.36 V and 18 mj.
The stimulation threshold was 2.5 V. We made
a threshold test that showed sinus rhythm at a 40 bpm
rate, and so the pacemaker was programmed to
a VOO mode and 60 bpm rate before the first RF
pulse was administered.
Interventional radiologists performed an ultra-
sound-guided approach to the previously described
lesions in hepatic segments 2 and 4–5 (Fig. 1).
A LeVeen Co-Access needle electrode system®
(Boston Scientific, 55, Av. Des Champs Pierreux,
TSA 51101, 92729, Nanterre, CEDEX, France) with
15 cm longitude and 3.5 cm length array was used
for the ablation procedure. The radio frequency ge-
nerator is a Boston Scientific Corporation RF ge-
nerator SC 545® (Boston Scientific Corporation,
One Boston Place, Natick MA, 01760-1537 USA).
The system uses four grounding electrodes applied
to the anterior and posterior aspects of both tighs,
which cannot be relocated to minimize the electric
field.
For the ablation of the dome lesion, an ante-
rior approach was used through the abdomen’s mid-
line. The needle’s insertion site was approximately
4 cm next to the pulse generator. The needle was
advanced toward the hepatic lesion with ultrasound
guidance. In that site, two RF applications were
done, the first for nine minutes with 150 W and an
average impedance of 60 W, the second for two and
a half minutes with 105 watts and 60 W. The neo-
plasm was about 7 cm of the device’s generator.
Both pulses were interrupted when measured
impedance rose up to 300 W.
To ablate the second lesion, an antero-lateral
approach was used through the rib cage in order to
reach the lesion that was approximately 14 cm away
from the pulse generator (Fig. 2). In that location,
two RF pulses were administered, the first of nine
minutes, 150 W and 60 W, the second of one and
a half minutes, 105 W, 58 W.
During the first RF, we could not identify any
RF-generated interference modifying the pacema-
ker’s functioning (Fig. 3A). The patient showed
a spontaneous increase in heart rate up to 70 bpm
in sinus rhythm, with normal atrioventricular (AV)
interval. Since the pacemaker was on a VOO mode,
the stimulation artifacts were clearly visible on the
T wave (Fig. 3B). The same Figure 3B shows an
increase in ventricular rate with complete AV block.
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That later returned to 60 bpm but with the pace-
maker in VOO mode there was no sensing of the
ventricular activity. The apparent AV conduction
could have been sympathetic activity related to the
RF pulse. Or it could have been an isorhythmic dis-
sociation. Since we had no intracardiac catheters,
the answer could not be determined.
We then reprogrammed the generator to a VVI
stimulation mode for the last set of RF pulses in the
lateral hepatic lesions and at a 50 bpm rate to limit
the R on T phenomenon (Fig. 3C). No RF-induced
interference was detected in either (Fig. 3D).
Interrogation of the device after the first and
second sets of RF pulses did not show any signifi-
cant differences in the battery or electrode status
(Table 1). Another threshold test was performed at
the end of the procedure and then we optimized the
stimulation parameters. No complications were de-
tected during or immediately after the procedure.
Discussion
Modern societies are exposed to a wide varie-
ty of electromagnetic wave sources. The biological
effects of such an electromagnetic surrounding are
apparently negligible, even if specific studies direc-
ted towards identification of potential biological
harm are scarce. Researchers have focused on can-
cer risk, genetic mutations and devices’ interactions
(cell phones — pacemakers) [10–14]. Although the-
re are potential risks for interference within seve-
ral devices, there is little information available about
this particular situation in which two different me-
dical equipments can have a potentially harmful in-
teraction.
Perhaps the most important fact regarding this
case is that even in conditions of proximity of the
hepatic lesions to a pulse generator that is unipolar
and in the limits of the pathway to the grounding
electrodes, no significant interference was registe-
red. We could hypothesize that the filtering capaci-
ties of the pacing device can safely distinguish the
interference’s frequency range, but that is beyond
Figure 1. Aproximate location of hepatic lesions; the arrowheads indicate the location of the pacemaker’s electrode.
Figure 2. Distance of hepatic lesions from pacemaker.
Pacemaker
Mitral prosthesis
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Figure 3. Electrocardiographic appearance during the radiofrequency (RF) procedure; A. Pre ablation unipolar VOO
programming with P waves visible (arrowheads); B. Unipolar VOO programming during ablation with sinus rhythm
present, fusion beats and R on T phenomenon; C. VVI programming before a new RF pulse with adequate ventricular
sensing and pacemaker inhibition; D. VVI programming during RF pulse with adequate ventricular sensing and
pacemaker inhibition. Two fusion beats are present.
Table 1. Pacemaker’s interrogated parameters.
Parameter Preablation Post ablation VOO Post ablation VVI
Battery impedance [W] 1956 2011 1838
Battery voltage [v] 2.74 2.74 2.74
Pulse duration [ms] 0.49 0.49 0.49
Pulse amplitude [v] 4.36 4.37 4.37
Pulse amplitude [mj] 18 17.3 17.3
Lead current [mA] 9.4 9 9
Lead impedance [W] 417 437 439
Stimulation threshold [v] 2.5 2.5
25 mm/seg
A
B
C
D
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the scope of this paper. Another possibility is that
the higher heart rate during RF could be interpre-
ted as a certain form of interference, but it also
could be related to a sympathetic activity increase
related to the RF application, specifically due to
some pain, even if the patient was mildly sedated.
The only potential complication came from the
fact that an increase in heart rate prompted an R on
T situation that was corrected resetting the pace-
maker to VVI mode, even in the theoretical risk of
having inhibition of the pacing device that did not
happen.
There is a recurrent concern regarding the
potential sources of electromagnetic interferences
that could affect pacing or antitachycardia devices.
A number of surgical interventions of several
types use electrocautery or RF sources that raise
concern about the potential harm of such interven-
tions on the normal functioning of permanently
implanted electronic devices [15–19]. The expe-
rience with abdominal ablation procedures shows
procedure-related complications that occur mainly
on the electrode imaging-guided placement and on
complications related to thermal injury. Apparen-
tly there has been little research regarding the in-
fluence on other implantable devices. The work by
Rhim et al. [9] mentions only 20 patients (2004) and
the work by Hayes et al. [3] only two. None of the
cases reported so far has showed pacemaker mal-
function or interference related to such procedures,
nor in patients with implantable cardioverter-defi-
brillators [15].
There are current recommendations issued by
Heart Rhythm Society regarding precautions that
must be observed while performing RF or electro-
cautery-related interventions [20] especially in pa-
tients wearing an cardioverter-defibrillator or pa-
cemaker. But even though caution must obviously
be taken, it seems that such interventions are sa-
fer than previously thought. Perhaps the filters in
modern pacemakers in the ranges previously men-
tioned allow a safe RF application without further
regard. More experience needs to be obtained be-
cause there are still safety ‘grey zones‘, and every
case that adds data to the available information can
be valuable.
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